Skip to content
Home/Companies/Biotech/Senti Biosciences

Senti Biosciences

Biotech·United States·Exited 2022·Held 1yr
Entry
2021
Hold
1yr
Exit
2022

Who owns Senti Biosciences?

Senti Biosciences was owned by Leaps by Bayer through Leaps by Bayer (2015 vintage) from 2021 to 2022, exited via IPO.

Hand-verified · updated 2026-07-16

Leaps by Bayer
Investor
Leaps by Bayer
Leaps by Bayer · 2015 · Evergreen

Key facts

HQUnited States
SectorBiotech
StatusAcquired
Exit Type
IPO
Buyer
–
MOIC
–
Exit Year
2022

More from Leaps by Bayer

Other portfolio companies in the same fund.

Celea Therapeutics
Celea Therapeutics
Active
BiotechUnited States· 2026
Leaf Agriculture
Active
ClimateTechUnited States· 2026
Sabanto
Active
AgTechUnited States· 2026
SonoThera
SonoThera
Active
BiotechUnited States· 2026
Souffle Therapeutics
Active
BiotechUnited States· 2025
WellTheory
WellTheory
Active
HealthTechUnited States· 2025

More PE-backed in Biotech

Comparable biotech deals from other GPs.

Antiverse
Antiverse
Active
Future Planet CapitalUK
CellCentric
CellCentric
Active
Future Planet CapitalUK
Crescendo Biologics
Crescendo Biologics
Active
Future Planet CapitalUK
Cytox Group
Exited 2024
Future Planet CapitalUK
GenSight Biologics
GenSight Biologics
Active
Sofinnova PartnersFrance
Healx
Healx
Active
Amadeus Capital PartnersUK
Track Senti Biosciences

Save this record to your watchlist and pick up your research where you left off. No spam.

Create free account

Get the full record on Senti Biosciences.

Free. No credit card. 30 seconds. Exit buyers and MOIC on Pro.

Hand-checked deal notes on this investment
Save this company to your watchlist
Exit buyer and MOIC on this deal (Pro)
or
Continue with email

Already a member? Sign in

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue